Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral antibiotic for uncomplicated urinary tract infections in adult women with limited or no alternative oral treatment options. After receiving FDA approval in October 2024, the company launched ORLYNVAH in the U.S. in August 2025 and is now building a commercial organization around sales, distribution, and supply chain execution.
1.41
1.41
| % | |
|---|---|
| Commercial pharmaceutical product | 85% ORLYNVAH™ is the company's approved oral antibiotic product sold in the U.S. for uUTI. |
| Commercialization services | 5% Sales, marketing, logistics, channel management, and medical affairs support outsourced to EVERSANA. |
| Manufacturing and supply chain | 5% Contract manufacturing and supply of ORLYNVAH materials through ACS Dobfar and related partners. |
| Development-stage pipeline | 5% Sulopenem-related research and development for potential future indications and products. |
The primary customers are U.S. prescribers and patients in the uncomplicated UTI market, with sales driven through...
Patients using ORLYNVAH when limited or no alternative oral antibacterial options are available.
Physicians and other clinicians targeted for adoption because they drive prescribing volume.
Commercial and public payers that affect formulary access, pricing, rebates, and net revenue.
Wholesalers, pharmacies, and fulfillment partners that handle inventory and dispensing.
EVERSANA and other vendors that manage commercialization, logistics, and compliance functions.
Iterum's business is currently centered in the United States, where ORLYNVAH was launched in August 2025 and where the...
The company's near-term strategy is to establish ORLYNVAH in the U.S. market through a focused launch, outsourced...
The company now needs product uptake to convert its first approved asset into sustainable revenue.
Reimbursement, distribution, and patient access will determine whether the launch can scale beyond early adoption.
Additional indications could broaden the addressable market and reduce reliance on a single product.
A new commercial product requires reliable manufacturing, inventory, and quality control to avoid launch disruption.
Iterum remains a high-risk commercial-stage biotech with a limited operating history, a single marketed product, and...
The company has incurred significant losses and has limited product revenue, so it may need additional capital to fund commercialization and development.
ORLYNVAH is newly launched and sales depend on prescriber uptake, access, and field execution in a competitive antibiotic market.
EVERSANA, ACS Dobfar, and other vendors handle key commercialization and supply functions outside direct control.
Errors in mandated pricing calculations or reporting could affect rebate liabilities and create False Claims Act exposure.
The Pfizer license is central to sulopenem rights and includes diligence, milestone, and royalty obligations.
The company handles patient, commercial, and safety data, and breaches could disrupt operations or trigger legal claims.
SPRO · Pharmaceutical Preparations
OTLK · Biological Products, (No Diagnostic Substances)
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
LRMR · Pharmaceutical Preparations
ATNM · Pharmaceutical Preparations
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
: 28/04/2026